Sinovac Reports Unaudited Third Quarter Financial Results -- Conference call scheduled for Thursday

Sinovac Reports Unaudited Third Quarter

-- Conference call scheduled for Thursday,

November 12, 2015 at 8:00 AM ET --

BEIJING, November 11, 2015 /PRNewswire/

-- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited

third quarter and nine month financial results for the period ended September 30, 2015.

Third Quarter 2015 Financial Highlights

(compared to the third quarter of

Quarterly sales were $16.8 million, a decrease

of 2.0% from $17.1 million in the comparative period. This decline was largely due to changes in exchange rate.

Gross profit was $11.2 million, a decrease

of 8.3% from $12.2 million in the prior year period. Gross margin was 66.4%, compared to 70.9% in the prior year period.

Net loss attributable to common shareholders

was $1.6 million, or $(0.03) per basic and diluted share, compared to net income attributable to common shareholders of $89,000,

or $0.00 per basic and diluted share, in the third quarter of 2014.

Mr. Weidong Yin, Chairman, President and

CEO of Sinovac, commented, "Our results this quarter reflect consistent recurring sales of our core products. We are pleased

to announce that the site inspection and GMP inspection for production of our EV71 vaccine have been completed, which is a critical

step in the final phase of the approval process. We expect to receive final approval for production from the CFDA by early next

year. Also, we were pleased to receive clinical trial approval for our varicella vaccine candidate. This live-attenuated vaccine

will be an important addition to our product portfolio and will serve as a component in our pipeline measles-mumps-rubella-varicella

(MMRV) combination vaccine. We continue to focus on maximizing the distribution of our core vaccine products, as we advance our

product pipeline to drive growth for years to come."

Third Quarter 2015 Business Highlights

In October, Sinovac received a tender from the Jiangsu provincial

government to be the supplier of hepatitis A vaccines for the third consecutive year. Under this agreement, Sinovac became the

sole supplier of the 2015 hepatitis A vaccine tender in Jiangsu for the first time and will provide 1.1 million doses of its inactivated

hepatitis A vaccines over the next 12 months to the Jiangsu provincial government.

As previously announced, Sinovac was also

awarded a tender from the Beijing government to supply seasonal influenza vaccines for its 2015 vaccination campaign. The Beijing

government plans to order a minimum of 1.2 million doses of the seasonal flu vaccine this year from four domestic vaccine manufacturers

Research and Development

EV71 The site inspection and GMP

inspection of the Company's EV71 vaccine production facility have been completed. The vaccine samples have passed the required

testing by the CFDA. Sinovac expects to receive final approval for its EV71 vaccine by early 2016.

Varicella Vaccine Sinovac obtained

approval from the CFDA to begin human clinical trials on its varicella vaccine candidate. The Company is currently confirming the

site, training staff and preparing for volunteer screening. Sinovac expects the clinical trials to be completed by 2017. Sinovac

is currently renovating an existing building on its Dalian campus, which will serve as the commercial production plant for the

varicella vaccine. The plant will have a designed annual capacity of 5,000,000 doses.

Unaudited Financial Results for Third

Total sales in the third quarter of 2015

were $16.8 million, a decrease of 2.0% compared to $17.1 million in the same period of 2014. The slight decrease is attributable

to the depreciation of the Chinese RMB against the US dollar.

Gross profit was $11.2 million in the third

quarter of 2015, compared to $12.2 million in the prior year period. Gross margin decreased to 66.4% from 70.9% in the prior year

period. The decrease is primarily due to a lower utilization rate of the Company's production facilities in 2015. Additionally,

in the third quarter of 2015, the Company delivered more Healive to the public market, which resulted in a lower average selling

price of products sold compared to the prior year period.

Selling, general and administrative expenses

in the third quarter of 2015 were $10.1 million, compared to $8.5 million in the same period of 2014. The increase was mainly due

to increased G&A expenses associated with the trial production of the EV71 vaccine for the site inspection.

R&D expenses in the third quarter of

2015 were $2.2 million, compared to $2.5 million in the same period of 2014.

Net loss attributable to common shareholders

for the third quarter of 2015 was $1.6 million, or $ (0.03) per basic and diluted share, compared to a net income attributable

to common shareholders of $89,000, or $0.00 per basic and diluted share, in the same period last year.

Unaudited Financial Results for nine

months ended September 30, 2015

Total sales in the first nine months of

2015 were $44.6 million, an increase of 4.2% from $42.8 million in the same period of 2014. The increase is primarily due to increased

sales of Healive into the public market and increased sales of Bilive into the private-pay market.

Gross profit in the first nine months of

2015 was $33.1 million, an increase of 5.1% from $31.5 million in the same period of 2014. Gross margin was 74.2%, compared to

73.6% in the same period of 2014.

Selling, general and administrative expenses

in the first nine months of 2015 were $26.2 million, compared with $24.9 million in the same period of 2014.The increase was mainly

due to increased G&A expenses associated with the trial production of the EV71 vaccine for the site inspection.

R&D expenses in the first nine months

of 2015 were $6.6 million, compared to $7.5 million in the same period of 2014.

Net loss attributable to common shareholders

in the first nine months of 2015 was $1.6 million, or $(0.03) per basic and diluted share, compared to net loss of $2.2 million,

or $(0.04) per basic and diluted share, in the same period of 2014.

As of September 30, 2015, cash and cash

equivalents totaled $54.4 million, compared to $91.5 million as of December 31, 2014. In the first nine months of 2015, net cash

used in operating activities was $11.0 million. Net cash used in investing activities was $3.4 million, which was for the payment

of property, plant and equipment. Net cash used in financing activities was $21.9 million, including loan proceeds of $14.4 million

and loan repayment of $37.2 million. As of September 30, 2015, the Company had $24.9 million of bank loans due within one year.

The Company expects that its current cash position will be able to support its operations for the next 12 months. The Company will

seek new commercial bank loans to finance the commercialization of its pipeline products and for other operational purposes when

Conference Call Details

Sinovac will host a conference call on

Thursday, November 12, 2015 at 8:00 a.m. ET (November12, 2015 at 9:00 p.m. China Standard Time) to review the Company's financial

results and provide an update on recent corporate developments. To access the conference call, please dial 1-877-407-9039

(USA) or 1-201-689-8470 (International). A replay of the call will be available from 11:00 a.m. ET on November13, 2015 through

November 27, 2015. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (International) and reference the replay

pin number 13616892.

A live audio webcast of the call will also

be available on the Investor Relations section of the Company's website at www.sinovac.com. A webcast replay will be available

on the Company's website for 30 days following the call.

Sinovac Biotech Ltd. is a China-based biopharmaceutical

company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human

infectious diseases. Sinovac's product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic

influenza (avian flu), H1N1 influenza (swine flu), mumps and canine rabies. In 2009, Sinovac was the first company worldwide to

receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling

program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. Sinovac

has filed a new drug application with the China Food & Drug Administration for its proprietary enterovirus 71 vaccine, having

been proven effective in preventing hand, foot and mouth disease in infants and children during its Phase III clinical trial. The